MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
METLIFE INC (MET) reported that director Carla A. Harris acquired 42 shares of common stock on September 8, 2026 through a grant/award transaction. The shares reflect imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors, bringing her direct holdings to 11,157 shares.
METLIFE INC (MET) director Robert Glenn Hubbard reported an acquisition of company common stock on September 8, 2026. He received 618 shares at an imputed price of $95.50 per share through reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors, bringing his directly held stake to 108,191 shares. The transaction was a compensation-related grant/award acquisition, and no Rule 10b5-1 trading plan is reported.
METLIFE INC (MET) director Jeh C. Johnson reported the acquisition of 59 shares of common stock on September 8, 2026 as a grant/award under a non-derivative transaction. The shares were credited at an imputed value of $95.50 per share through reinvested dividends on deferred shares.
Following this imputed dividend reinvestment under the MetLife Deferred Compensation Plan for Non-Management Directors, Johnson now holds 9,557 shares of MetLife common stock in direct ownership, representing deferred shares that have become payable but whose receipt he has elected to defer. No Rule 10b5‑1 trading plan is reported for this transaction.
METLIFE INC (MET) director Diana McKenzie reported an acquisition of company common stock tied to director compensation. On September 8, 2026, she received 157 shares of common stock at an imputed price of $95.50 per share through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this award, she directly holds 25,385 shares of MetLife common stock. No Rule 10b5-1 trading plan is reported for this transaction.
METLIFE INC (MET) reported that director Daniel S. Glaser acquired 10 shares of common stock on September 8, 2026 through an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors at a reference value of $95.50 per share. Following this grant, he holds 2,705 shares directly and an additional 198 shares indirectly through a GRAT.
METLIFE INC (MET) reported that executive vice president Bill Pappas had 4,030 shares of common stock withheld on August 31, 2026 at $95.17 per share to pay tax liabilities on shares issued for restricted stock units. After this withholding, he holds 79,716 shares directly, plus 10,220 shares indirectly through a 2024 GRAT and 18,750 shares indirectly through a 2025 GRAT.
METLIFE INC (MET) reported that EVP & Chief Financial Officer John D. McCallion had 6,057 shares of common stock withheld on August 31, 2026 to pay tax liabilities related to vested restricted stock units at a price of $95.17 per share. Following this withholding, he directly holds 269,137 shares of MET common stock; no Rule 10b5-1 trading plan is reported.
METLIFE INC (MET) reported an insider transaction by EVP & Chief Risk Officer Marlene Debel on August 31, 2026. Debel had 4,030 shares of Common Stock withheld to pay tax liabilities on shares issued from restricted stock units, at a reference price of $95.17 per share. This was not an open-market sale but a tax-withholding disposition, and Debel held 150,350 shares of MetLife common stock directly after the transaction. No Rule 10b5-1 trading plan is reported for this filing.
METLIFE INC (MET) reported that Ramy Tadros, President, U.S. Business, had 4,366 shares of common stock disposed of on August 31, 2026 to satisfy tax obligations on recently vested restricted stock units. The shares were withheld by the company for tax payment, and he directly holds 212,580 shares afterward.
METLIFE INC (MET) filed a notice under Rule 144 covering a proposed sale of 15,400 shares of common stock for the account of a Separate Account, with Barclays as broker and sales expected on or about 08/28/2026 on the NYSE. The filing states that 635,476,927 shares of MetLife common stock were outstanding. It also lists recent Rule 144 sales from various Separate Accounts and MetLife 401k plan trusts, including 128 shares for gross proceeds of $10,490.88 on 05/28/2026 and 332 shares for $28,412.56 on 06/18/2026.